Regulation of apo A-I gene expression by fibrates

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Staels, Bart ^a   Auwerx, Johan ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoprotein; Fibrate hypolipidemic; High density lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

CONFERENCE PAPER; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; LIPOPROTEIN SYNTHESIS; LIVER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

EID: 0031748864     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00313-4     Document Type: Conference Paper

References (21)

1. Staels B, Van Toi A, Andren T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 1992;12:286-94.
2. Staels B, Peinado-Onsurbe J, Auwerx J. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim Biophys Acta 1992;1123:227-30.
3. Staels B, van Tol A, Skretting G, Auwerx J. Lecithin: cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. J Lipid Res 1992;33:727-35.
4. Staels B, van Tol A, Verhoeven G, Auwerx J. Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. Endocrinology 1990;126:2153-63.
5. Berthou L, Saladin R, Yaqoob P, Branellec D, Calder P, Fruchart JC, Denefle P, Auwerx J, Staels B. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995;232:179-87.
6. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
7. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
8. Isseman I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
9. Lee SS, Pineau T, Drago J, Lee J, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez. FJ. Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
10. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharmaceutical Des 1997;3:1-14.
11. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidology 1997;8:159-66.
12. Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc R Soc London Biol 1992;247:83-7.
13. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPARα,β and γ in the adult rat. Endocrinology 1995;137:354-66.
14. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARa-leukotriene B4 pathway to inflammation control. Nature 1996;384:39-43.
15. Peters JM, Hennuyer N, Staels B, Fruchart J-C, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in PPARα-deficient mice. J Biol Chem 1997;272:27307-12.
16. Sirtori CR, Catapano A, Paoletti R. Therapeutic significance of hypolipidemic and antiatherosclerotic drugs. Atherosclerosis Rev 1977;2:113-52.
17. Lussier-Cacan S, Bard J-M, Boulet L, Nestruck AC, Grothé A-M, Fruchart J-C, Davignon J. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 1989;78:167-82.
18. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994;269:31012-8.
19. Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart J-C, Rubin E, Denèfle P, Staels B, Branellec D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. J Clin Invest 1996;97:2408-16.
20. Saitoh K, Mori T, Kasai H, Nagayama T, Tsuchiya A, Ohbayashi S. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. Folia Pharmacol Jpn 1995;106:41-50.
21. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine L-M, Branellec D, Fruchart J-C, Auwerx J, Fiévet C, Duverger N, Staels B. The beneficial effects of fibrates on high density lipoprotein metabolism occur independent of any peroxisome proliferative response. Circulation 1997;96:I-662.